Pharma BD Deal Intelligence
Novo Nordisk's up-to-$1.46B molecular glue collaboration with Neomorph pushes its cardiometabolic pipeline past Ozempic and Wegovy, but with Neomorph only leading discovery and preclinical work, the deal's real value depends entirely on assets that haven't reached the clinic yet.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novo Nordisk is venturing into the molecular glue degrader space with a multi-target deal with San Diego-based Neomorph worth up to $1.46 billion in biobucks.…
Neomorph has landed a multi-target collaboration with Novo Nordisk worth up to $1.46 billion in potential payments across multiple programs, plus upfront,…
Apr 17, 2026: Neomorph closed a $100M Series B led by Deerfield Management (with Regeneron Ventures, Longwood, Alexandria, Binney Street). Funds the Phase…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Neomorph entered multi-target collaboration and licensing agreement with Novo Nordisk for molecular glue degraders in cardiometabolic and rare diseases. Total deal value up to $1.46B across multiple targets, plus upfront, R&D funding, and tiered royalties. Neomorph leads discovery and preclinical work with Novo Nordisk holding exclusive clinical and commercialization rights.
145M US cases/yr · $120.0B Global Cardiometabolic Therapeutics Market (2024)
The Novo Nordisk-Neomorph collaboration is a platform agreement spanning cardiometabolic and rare disease targets rather than a single indication. Cardiometabolic disease encompasses obesity (~100 million US adults), type 2 diabetes (~38 million), atherosclerotic cardiovascular disease, heart failure, non-alcoholic steatohepatitis (MASH/MASLD, ~17 million), and chronic kidney disease, collectively representing the largest disease burden globally and Novo Nordisk's strategic core beyond its GLP-1 franchise. Rare diseases include thousands of monogenic and oligogenic conditions affecting <200,000 US patients each; Novo Nordisk maintains rare hematologic (hemophilia A/B via NovoSeven, Refixia, Esperoct) and rare endocrine programs (growth hormone disorders via Norditropin, Sogroya). Many high-value cardiometabolic and rare disease targets are transcription factors, scaffolding proteins, or membrane-bound regulators historically classified as undruggable by small-molecule inhibitors. Molecular glue degraders redirect E3 ubiquitin ligases (CRBN, DCAF15, DDB1-CUL4, RNF114) to catalytically degrade these proteins, offering advantages over occupancy-based inhibition including substoichiometric activity, resistance breakdown, and oral bioavailability. The modality is clinically validated by IMiDs (lenalidomide, pomalidomide) in hematologic malignancy and increasingly pursued by major pharma for cardiometabolic and immunology targets.
The molecular glue and targeted protein degradation competitive landscape is dense across commercial and discovery stages. Approved molecular glues from Bristol Myers Squibb: Revlimid (lenalidomide), Pomalyst (pomalidomide), Thalomid (thalidomide), and CELMoDs iberdomide (CC-220) and mezigdomide (CC-92480) anchor the commercial category. Molecular glue platform companies include Neomorph itself (Novo Nordisk, Biogen partnerships within a single year), Monte Rosa Therapeutics (QuEEN platform; MRT-2359 GSPT1 degrader partnered with Novartis), C4 Therapeutics (CFT1946 BRAF V600E; CFT8634 BRD9, Roche partnership), Kymera Therapeutics (KT-474 IRAK4 partnered with Sanofi; KT-253 MDM2; KT-621 STAT6 for atopic dermatitis), Arvinas (ARV-471/vepdegestrant ER partnered with Pfizer; ARV-766 AR), Foghorn Therapeutics (Eli Lilly partnership), Nurix Therapeutics (Gilead and Sanofi partnerships including NX-5948 BTK), Plexium, Captor, Orum Therapeutics, Proxygen (Boehringer partnership), Vividion (Bayer/Roivant), and Biotheryx. Novo Nordisk's own cardiometabolic franchise is anchored by Ozempic/Wegovy (semaglutide GLP-1), Rybelsus (oral semaglutide), Saxenda (liraglutide), and pipeline CagriSema (cagrilintide+semaglutide) and amycretin (oral GLP-1/amylin), contextualizing molecular glue as a discovery-stage modality complement to Novo's GLP-1 commercial portfolio and a hedge against eventual GLP-1 class commoditization.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Neomorph Inc. (this deal) | 2024 | $1.5B | — |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
← Browse all deals · How we score deals
More: 2024 deals · Novo Nordisk A/S deals · Rare Disease deals